Role of P2Y receptor subtypes in platelet-derived microparticle generation

Bryan N Kahner1, Robert T Dorsam, Satya P Kunapuli

  • 1Department of Physiology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA

Insights

The P2Y12 receptor, not the P2Y1 receptor, significantly reduces microparticle formation from activated platelets. This suggests P2Y12

Area of Science:

  • Hematology
  • Platelet Biology
  • Thrombosis

Background:

  • Platelet activation leads to microparticle shedding, contributing to clot formation.
  • P2Y1 and P2Y12 receptors play distinct roles in platelet function.

Purpose of the Study:

  • To investigate the specific roles of P2Y1 and P2Y12 receptors in platelet microparticle formation.
  • To determine the contribution of each receptor to platelet activation and microparticle release.

Main Methods:

  • Utilized P2Y1 and P2Y12 receptor antagonists (MRS2179 and AR-C 69931MX, respectively) in platelet activation assays.
  • Compared microparticle formation in P2Y1 knockout mice versus wild-type mice.
  • Administered strong agonists like convulxin and thrombin to induce platelet activation.

Main Results:

  • P2Y12 receptor antagonist AR-C 69931MX significantly decreased microparticle formation.
  • P2Y1 receptor antagonist MRS2179 did not significantly affect microparticle formation.
  • P2Y1 knockout mice showed no significant difference in microparticle formation compared to wild-type mice.

Conclusions:

  • P2Y12 receptor is crucial for microparticle formation from platelets activated by strong agonists.
  • P2Y1 receptor plays a minimal role in agonist-induced microparticle formation.
  • Increased bleeding time in P2Y1 null mice is linked to general platelet dysfunction, not reduced microparticles.

Related Concept Videos

Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...